HIV 	HIV 	 NNP	B-NP
/ 	/ 	 NNP	I-NP
HCV-coinfection 	HCV-coinfection 	 NNP	I-NP
:  	:  	 :	O
which  	which  	 WDT	O
role  	role  	 NN	O
can  	can  	 MD	O
new  	new  	 JJ	O
antiretrovirals  	antiretrovirals  	 JJ	O
such  	such  	 JJ	O
as  	as  	 IN	O
integrase  	integrase  	 JJ	B-NP
inhibitors  	inhibitors  	 JJ	I-NP
play 	play 	 NN	I-NP
?  	?  	 .	O
End-stage  	End-stage  	 JJ	B-NP
liver  	liver  	 NN	I-NP
disease  	disease  	 NN	I-NP
has  	has  	 VBZ	O
become  	become  	 VBN	O
one  	one  	 CD	O
of  	of  	 IN	O
the  	the  	 DT	O
most  	most  	 RBS	O
frequent  	frequent  	 JJ	O
causes  	causes  	 NNS	O
of  	of  	 IN	O
death  	death  	 NN	O
in  	in  	 IN	O
HIV 	HIV 	 NNP	B-NP
/ 	/ 	 NNP	I-NP
HCV-coinfected  	HCV-coinfected  	 JJ	I-NP
patients 	patients 	 NNS	I-NP
.  	.  	 .	O
The  	The  	 DT	O
role  	role  	 NN	O
of  	of  	 IN	O
new  	new  	 JJ	O
antiretrovirals  	antiretrovirals  	 NN	B-NP
in  	in  	 IN	O
the  	the  	 DT	O
progression  	progression  	 NN	O
of  	of  	 IN	O
liver  	liver  	 JJ	O
fibrosis  	fibrosis  	 NN	O
has  	has  	 VBZ	O
yet  	yet  	 RB	O
to  	to  	 TO	O
be  	be  	 VB	O
defined 	defined 	 VBN	O
.  	.  	 .	O
However  	However  	 RB	O
with  	with  	 IN	O
significant  	significant  	 JJ	O
toxicities  	toxicities  	 NN	O
and  	and  	 CC	O
drug-to-drug  	drug-to-drug  	 JJ	B-NP
interactions  	interactions  	 NNS	I-NP
of  	of  	 IN	I-NP
nucleoside  	nucleoside  	 JJ	I-NP
reverse  	reverse  	 JJ	I-NP
transcriptase  	transcriptase  	 JJ	I-NP
inhibitors  	inhibitors  	 NN	I-NP
in  	in  	 IN	O
combination  	combination  	 NN	O
with  	with  	 IN	O
ribavirin 	ribavirin 	 NN	O
,  	,  	 ,	O
with  	with  	 IN	O
drug  	drug  	 NN	O
to  	to  	 TO	O
drug  	drug  	 NN	B-NP
interaction  	interaction  	 NN	I-NP
of  	of  	 IN	O
HIV  	HIV  	 NNP	B-NP
protease  	protease  	 VBD	O
inhibitors  	inhibitors  	 VBN	O
with  	with  	 IN	O
HCV  	HCV  	 NNP	B-NP
protease  	protease  	 NN	O
inhibitors  	inhibitors  	 NNS	O
and  	and  	 CC	O
calcineurin-inhibitors 	calcineurin-inhibitors 	 JJ	B-NP
,  	,  	 ,	O
new  	new  	 JJ	O
antiretrovirals  	antiretrovirals  	 NNS	B-NP
lacking  	lacking  	 VBG	O
these  	these  	 DT	O
interactions  	interactions  	 NNS	B-NP
represent  	represent  	 VBP	O
attractive  	attractive  	 JJ	O
alternatives  	alternatives  	 NNS	O
in  	in  	 IN	O
the  	the  	 DT	O
setting  	setting  	 NN	O
of  	of  	 IN	O
anti-HCV  	anti-HCV  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
or  	or  	 CC	O
post  	post  	 VB	O
liver  	liver  	 JJ	B-NP
transplantation 	transplantation 	 NN	I-NP
.  	.  	 .	O
In  	In  	 IN	O
the  	the  	 DT	O
following  	following  	 JJ	O
review  	review  	 NN	O
we  	we  	 PRP	O
want  	want  	 VBP	O
to  	to  	 TO	O
focus  	focus  	 VB	O
on  	on  	 IN	O
the  	the  	 DT	O
new  	new  	 JJ	O
class  	class  	 NN	O
of  	of  	 IN	O
HIV  	HIV  	 NNP	B-NP
integrase  	integrase  	 NN	O
inhibitors  	inhibitors  	 NNS	O
and  	and  	 CC	O
discuss  	discuss  	 VB	O
present  	present  	 JJ	O
data  	data  	 NNS	O
with  	with  	 IN	O
regard  	regard  	 NN	O
to  	to  	 TO	O
special  	special  	 JJ	O
issues  	issues  	 NNS	O
of  	of  	 IN	O
HIV  	HIV  	 NNP	B-NP
and  	and  	 CC	O
HCV  	HCV  	 NNP	B-NP
co-infection 	co-infection 	 NNP	O
.  	.  	 .	O
